The identification of target mRNAs is a key step for assessing the role of aberrantly expressed microRNAs in human cancer. MiR-221 is upregulated in human hepatocellular carcinoma (HCC) as well as in other malignancies. One proven target of miR-221 is CDKN1B/p27, whose downregulation affects HCC prognosis. Here, we proved that the cyclin-dependent kinase inhibitor (CDKI) CDKN1C/p57 is also a direct target of miR-221. Indeed, downregulation of both CDKN1B/p27 and CDKN1C/p57 occurs in response to miR-221 transfection into HCCderived cells and a significant upregulation of both CDKN1B/p27 and CDKN1C/p57 occurs in response to antimiR-221 transfection. A direct interaction of miR-221 with a target site on the 3 0 UTR of CDKN1C/p57 mRNA was also demonstrated. By controlling these two CDKIs, upregulation of miR-221 can promote growth of HCC cells by increasing the number of cells in S-phase. To assess the relevance of these studies in primary tumors, matched HCC and cirrhosis samples were assayed for miR-221, for CDKN1B/p27 and CDKN1C/p57 expression. MiR-221 was upregulated in 71% of HCCs, whereas CDKN1B/p27 and CDKN1C/p57 proteins were downregulated in 77% of cases. A significant inverse correlation between miR-221 and both CDKN1B/p27 and CDKN1C/p57 was found in HCCs. In conclusion, we suggest that miR-221 has an oncogenic function in hepatocarcinogenesis by targeting CDKN1B/p27 and CDKN1C/p57, hence promoting proliferation by controlling cell-cycle inhibitors. These findings establish a basis toward the development of therapeutic strategies aimed at blocking miR-221 in HCC.
Introduction
Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers and it represents the fifth more common cancer worldwide, with an increasing incidence expected in the next decades (Bosch et al., 2004) . The diffusion of surveillance programs of cirrhotic patients has led to an increased detection of HCC at an early stage (Sangiovanni et al., 2004) , however only 30-40% of patients with a newly diagnosed HCC can be curatively treated in the western countries (Bolondi, 2003) . Despite curative treatments offer a 5-year survival rate of 50-70% (Bruix and Sherman, 2005) , recurrences after resection exceed 70% at 5 years and are due to either metachronic tumors arising in cirrhosis or to disseminated tumor sites understaged at preoperative imaging studies in 10-15% of cases (Lencioni et al., 2005) . HCC is poorly responsive to conventional chemotherapeutic agents, which can even be toxic due to liver functional impairment associated with cirrhosis and to hemathologic adverse indications linked to hypersplenism. Thus, at least two clinical settings suggest the urgent need to develop new types of treatment for HCC: patients with HCC not amenable for curative treatments and patients curatively treated for HCC in which a recurrence rate over 70% at 5 years is expected (Bruix and Sherman, 2005) .
MicroRNAs (miRNAs) are a class of genes encoding short RNAs, which control gene expression by inhibiting translation or inducing cleavage of target mRNAs. MiRNAs are aberrantly expressed in cancer tissues and links between deregulated miRNAs and molecular pathways involved in carcinogenesis have been established (Negrini et al., 2007) . The therapeutic use of miRNAs has been suggested and miRNA inhibitors, the 'antagomirs', have been developed to inhibit the action of endogenous miRNAs (Krutzfeldt et al., 2005) . We have recently described the upregulation of miR-221 in HCC (Gramantieri et al., 2007) . Similar evidences have been reported in glioblastoma (Ciafre`et al., 2005) , urinary bladder cancer (Gottardo et al., 2007) , papillary tumors of the thyroid (He et al., 2005) and pancreatic cancer (Lee et al., 2006) , which support an oncogenic role for this miRNA in different human neoplasms. Moreover, overexpression of miR-221 was shown to promote cancer cell proliferation, most likely by its ability to modulate the expression of the oncogenic protein c-kit (Felli et al., 2005) and of the cyclindependent kinase inhibitor (CDKI) CDKN1B/p27 (Galardi et al., 2007; Gillies and Lorimer, 2007; Le Sage et al., 2007; Visone et al., 2007) , an important controller of cell-cycle progression.
CDKN1B/p27 was reported to be downregulated in HCC tissue in comparison with surrounding cirrhosis. The downregulation of CDKN1B/p27 exhibits a relevant prognostic significance in human HCC, as it is associated with advanced tumor stage, poor survival and recurrence of small HCC (Tannapfel et al., 2000) . The Cip/KIP family of CDKIs (cyclin-dependent kinase inhibitors) includes also CDKN1A/p21 and CDKN1C/ p57. Downregulation of CDKN1C/p57 in HCC was also shown to correlate with a higher biological aggressiveness, advanced stage, poor differentiation, larger size, portal invasion and high proliferative activity. Furthermore, a low CDKN1C/p57 labeling index was associated with worse outcomes and lower disease-free survival after surgery, suggesting that CDKN1C/p57 downregulation might contribute to the progression of HCC through modulation of cell growth (Ito et al., 2001; Nakai et al., 2002) .
We and other groups have previously reported that about 26% of HCCs exhibit a loss of maternal allele methylation at the KvDMR1 imprinted locus at 11p15.5, where CDKN1C/p57 gene is located (Schwienbacher et al., 2000; Diaz-Meyer et al., 2003) , and this mechanism has been linked to reduction of CDKN1C/ p57 expression (Soejima et al., 2004) . However, in unselected series of HCCs, we have observed a downregulation of CDKN1C/p57 in about 80% of HCCs with reference to matched cirrhosis, therefore CDKN1C/p57 downregulation is likely to rely upon additional molecular mechanisms besides aberrant methylation. As bioinformatic predictions indicate that CDKN1C/p57 is a possible target of miR-221, but no experimental data are actually available, in this study we aimed at investigating the role of miR-221 in the regulation of CDKN1B/p27 and CDKN1C/p57 in HCC. As reported for other human malignancies, CDKN1B/p27 turned out to be regulated by miR-221; in addition, we proved for the first time that CDKN1C/ p57 is also a direct target of miR-221.
Results

CDKN1C/p57 and CDKN1B/p27 are targets of miR-221
To study the role of miR-221 in hepatocarcinogenesis and to identify its putative target genes we performed a bioinformatic analysis by using miRanda, TargetScan and PicTar algorithms. CDKN1B/p27 and CDKN1C/ p57 mRNAs are both predicted by at least two of the algorithms and reveal potential miR-221 target sites in their 3 0 -UTR regions. The Hep3B cell line was chosen for both miR-221 and antimiR-221 transfection because its exhibits, among the three cell lines tested (Hep3B, SNU398 and SNU449), an intermediate miR-221 expression levels and a fairly high CDKN1C/p57 and CDKN1B/p27 protein levels ( Figure 1a ). In comparison with negative control 1 precursor miRNAs, transfection of miR-221 into Hep3B cells caused a 1.8-and 2.6-fold decrease of CDKN1C/ p57 and CDKN1B/p27 protein levels, respectively (Figure 1b) . On the contrary, Hep3B cells transfected with antimiR-221 exhibited a 1.9-and 1.4-fold increase in CDKN1C/p57 and CDKN1B/p27 protein levels, respectively, when compared with negative control 1 miRNA inhibitors (Figure 1c ). To further confirm the Hep3B results, transfection of miR-221 in SNU398 cells, which express very low intrinsic levels of miR-221 and the highest CDKN1C/p57 and CDKN1B/p27 protein levels ( Figure 1a ), resulted in a 3.4-and 1.9-fold decrease of CDKN1C/p57 and CDKN1B/p27 protein levels, respectively, when compared with negative controltreated cells (Figure 1d ). AntimiR-221 transfection was not performed in SNU398 cells because of their very low constitutive miR-221 expression. In addition, we also performed miR-221 silencing in SNU449 cell line, which expresses high miR-221 and low CDKIs basal levels ( Figure 1a ). SNU449 cells transfected with antimiR-221 exhibited a 1.3-and 2.0-fold increase in CDKN1C/p57 and CDKN1B/p27 protein levels, respectively, when compared with negative control 1 miRNA inhibitors (Figure 1e ).
MiR-221 interacts with 3
0 UTR of CDKN1C/p57 mRNA To demonstrate the direct interaction between miR-221 and CDKN1C/p57 mRNA, we cloned a 262 bp CDKN1C/p57 3 0 -UTR segment, which includes a potential target site for miR-221 (Figure 2a ), downstream of the pGL3 luciferase reporter gene to generate the pGL3-p57 vector. This vector was co-transfected into Hep3B or SNU449 HCC-derived cell lines together with miR-221, or antimiR-221 or scrambled miRNAs negative control. A renilla luciferase vector (pRL-TK) was used to normalize differences in transfection efficiency. Luciferase activity in Hep3B cells co-transfected with pGL3-p57 vector and miR-221 was decreased by 29% when compared with negative control 1 miRNA precursors (P ¼ 0.001 at t-test) (Figure 2b ). Conversely, luciferase activity in SNU449 cells transfected with antimiR-221 was increased of 27%, a statistically significant difference, when compared with negative control 1 miRNA inhibitors (P ¼ 0.0008 at t-test) (Figure 2c ). We did not further investigated the direct interaction between miR-221 and CDKN1B/p27 mRNA 3 0 -UTR target sites because it has already been demonstrated by several studies (Galardi et al., 2007; Gillies and Lorimer, 2007; Le Sage et al., 2007;  miR-221 targets CDKN1C/p57 and CDKN1B/p27 F Fornari et al Visone et al., 2007) . Taken together, immunoassay and luciferase results provided strong indications that CDKN1C/p57 as well as CDKN1B/p27 are both targets of miR-221 in HCC cells.
MiR-221 influences cell growth and cell cycle of HCC-derived cell lines Because of the regulation of two CDKIs, we assessed the role of miR-221 in the regulation of cell growth in HCC-derived cell lines. We transfected miR-221 and antimiR-221 into Hep3B cells, which exhibit intermediate levels of miR-221. MiR-221 overexpression caused a 30% increase in cell number when compared to negative control 1 precursor molecules (P ¼ 0.011 at t-test), and, in line with this finding, miR-221 silencing by antimiR-221 caused a 30% decrease in cell number, when compared to negative control cells (P ¼ 0.003 at t-test) (Figure 3a) . To further confirm the role of miR-221 in Western blot analyses of CDKN1C/p57 and CDKN1B/p27 expression in Hep3B cells transfected with miR-221 revealed a decrease of CDKN1C/p57 and CDKN1B/p27 protein levels (1.8-and 2.6-fold decrease, respectively). (c) Western blot analyses of CDKN1C/p57 and CDKN1B/p27 expression after antimiR-221 transfection in Hep3B cells revealed an increase in CDKN1C/p57 and CDKN1B/p27 expression (1.9-and 1.4-fold, respectively).
(d) Western blot analyses of CDKN1C/p57 and CDKN1B/p27 expression in SNU398 cells transfected with miR-221 revealed a decrease of CDKN1C/p57 and CDKN1B/p27 protein levels (3.4-and 1.9-fold decrease, respectively). (e) Western blot analyses of CDKN1C/p57 and CDKN1B/p27 expression after antimiR-221 transfection in SNU449 cells revealed an increase in CDKN1C/p57 and CDKN1B/p27 expression (1.3-and 2.0-fold, respectively). miR-221, antimiR-221 and Ambion's negative control 1 precursor microRNAs (miRNAs) were all transfected at 100 nM. miR, miR-221 microRNA; anti, antimiR-221 microRNA inhibitor; NC, negative control 1 precursor miRNA.
miR-221 targets CDKN1C/p57 and CDKN1B/p27 F Fornari et al regulating cell growth, we overexpressed miR-221 in a second HCC-derived cell line, SNU398, which expresses the lowest miR-221 levels among the tested cell lines. In comparison with cells transfected with negative control, at 24 and 48 h following miR-221 transfection, a 35% (P ¼ 0.002 at t-test) and 30% (P ¼ 0.0006 at t-test) increase in cell number was observed, (Figure 3b ). We then performed a flow cytometry analysis to investigate Hep3B cell-cycle phase distribution. This analysis revealed that Hep3B cells overexpressing miR-221 had a 1.8-fold (75%) increase in the S-phase population and a concomitant 14% decrease of the G 1 population, when compared to cells transfected with negative control (Figure 3c ).
In vivo regulation of CDKN1B/p27 and CDKN1C/p57 by miR-221 To assess the significance of these findings in primary tumors, we selected a group of samples on the basis of similar CDKN1C/p57 mRNA levels in HCC and matched cirrhosis, to avoid the 25-30% of HCCs in which CDKN1C/p57 is affected by aberrant methylation at 11p15.5. Among the 39 initial series of matched 0 UTR of the vector pGL3-p57, containing 262 bp of the CDKN1C/p57 3 0 UTR, as evaluated by luciferase activity in Hep3B cells. Firefly luciferase reporter activity is significantly decreased when pGL3-p57 vector is co-transfected with miR-221 (P ¼ 0.001, t-test). On the contrary luciferase activity of the pGL3 vector alone is not significantly affected by miR-221. (c) Luciferase assay of pGL3-p57 and antimiR-221 in SNU449 cells. Firefly luciferase reporter activity is significantly increased when pGL3-p57 vector is co-transfected with antimiR-221 (P ¼ 0.0008, t-test), whereas an equivalent increase is not observed when pGL3 control vector is used. Firefly luciferase activity was normalized on Renilla luciferase activity of the co-transfected pRL-TK vector. Each data were repeated twice in triplicate. Average ± s.d. values are shown.
HCC and cirrhotic tissues, 35 cases were selected because they displayed similar CDKN1C/p57 mRNA levels. Of 35 cases 27 (77%) exhibited CDKN1C/p57 protein downregulation in HCC with regard to matched cirrhosis. Significantly, the observed downregulation was not present at the RNA level, indicating that the protein downregulation was post-transcriptionally regulated. A selection of cases is reported in Figure 4a . To assess the existence of an inverse correlation between miR-221 expression and CDKN1B/p27 or CDKN1C/ p57 protein levels in HCC, we performed quantitative real-time RT-PCRs of miR-221 and western blot analyses of CDKN1B/p27 and CDKN1C/p57 in the 35 matched cirrhotic and HCC tissues. As shown in Figures 4b and c , when CDKN1C/p57 or CDKN1B/p27 protein levels were plotted against miR-221 expression, an inverse correlation (two-tailed Pearson's test: Po0.0001 for both the CDKIs) was found. No association was found between miR-221 levels and the causes of underlying liver disease, in particular with viral infections, gender, histopathological grading and a-fetoprotein levels.
Discussion
The early diagnosis and improvements in HCC treatment has positively impacted survival of HCC patients over the past decade (Sangiovanni et al., 2004) . However a consistent percentage of patients still cannot be curatively treated at the time of diagnosis or develop adverse indications for treatments during the course of the disease. Thus, the awareness that HCC is the leading cause of death in compensated cirrhosis has led to investigate new approaches targeting molecular abnormalities specific to HCC. New targeted therapies directed against molecules involved in the pathogenesis of cancer were recently reported as safe and effective in several tumors. Oral multikinase inhibitors, in particular, have been recently tested in patients with nonsurgical HCC providing the evidence of a moderate efficacy and a manageable toxicity (Abou-Alfa et al., 2006; Llovet et al., 2007) .
MiRNAs were recently discovered as important players in human (Calin and Croce, 2006) and their role as therapeutic targets has been proposed (Krutzfeldt et al., 2005) . Nevertheless, in spite of the discovery of various miRNA targets implicated in human cancer (Cimmino et al., 2005; Johnson et al., 2005; O'Donnell et al., 2005) , most mechanisms by which miRNAs are involved in tumorigenesis remain to be elucidated. Indeed, the identification of cancer-specific miRNA targets is critical for understanding the functional role of miRNAs in carcinogenesis and may be important for defining novel therapeutic molecules. In this view, the liver represents an ideal organ for oligonucleotide-based therapies for several reasons. First, the liver is extremely receptive to the uptake of peripherally administered oligonucleotides. Experimental findings on the real effectiveness of antagomirs on hepatocytes biosynthetic functions have been reported in mice following endovenous administration (Krutzfeldt et al., 2005) . Second, efficient ways for the selective drug delivery in HCC feeding arteries have been developed and routinely used in the clinical practice during superselective transarterial chemoembolization of HCC nodules. Such a way for drug delivery could be used also for miRNA inhibitors, to prevent possible toxic side effects in nonneoplastic liver. Third, miR-221 is selectively upregulated in several human cancers and evidences supporting its role in carcinogenesis and increased cell growth have been reported (Felli et al., 2005; Galardi et al., 2007; Gillies and Lorimer, 2007; Le Sage et al., 2007; Visone et al., 2007) . MiR-221 represents therefore an attractive candidate for selective treatments with antagomirs. In a previous report (Gramantieri et al., 2007) , we identified miR-221 as upregulated in 70% of HCCs with b-Actin was used as housekeeping gene to normalize CDKN1C/p57 expression, both at mRNA and protein level. A reduction of CDKN1C/p57 protein levels can be observed in HCC tissues, despite mRNA levels were not different when compared to matched cirrhosis. Cases are numbered according to Table 1 . Inverse correlation between miR-221 and CDKN1C/p57 (b) and miR-221 and CDKN1B/p27 (c) in hepatocellular carcinoma tissues. MiR-221 quantitation was obtained by real-time RT-PCR, whereas CDKN1B/p27 and CDKN1C/p57 protein expression was evaluated by western blot. Each data from HCC samples were referred to matched cirrhosis and expressed into log2 form. A statistically significant correlation between miR-221 and CDKN1B/p27 and between miR-221 and CDKN1C/p57 protein levels (Po0.001 for both CDKI) was observed by using two-tailed Pearson's test. (Galardi et al., 2007; Gillies and Lorimer, 2007; Le Sage et al., 2007; Visone et al., 2007) . In addition, we report that another CDKI, CDKN1C/p57, is also a direct target of miR-221 in the liver. CDKN1C/p57 modulation by miR-221 was demonstrated by in vitro transfection experiments in HCC-derived cell lines and by proving the direct interaction between miR-221 and CDKN1C/ p57 3 0 -UTR target site using a luciferase assay. We also proved the existence of an inverse correlation between miR-221 and CDKN1C/p57 protein expression in primary HCCs.
CDKN1C/p57 is an important factor controlling cell cycle. Cells lacking CDKN1C/p57 show increased cell growth and decreased differentiation (Yan et al., 1997; Zhang et al., 1997) . With regard to the role of CDKN1C/p57 in hepatocarcinogenesis, previous reports showed that CDKN1C/p57 is downregulated in HCC. Notably, loss of CDKN1C/p57 protein expression in HCC tissue was associated with a higher aggressiveness, worse outcomes and lower disease-free survival (Nakai et al., 2002) . CDKN1C/p57 downregulation in HCC tissues has also been intimately associated with PCNA overexpression, indicating an increased proliferating activity and a poorer prognosis (Nan et al., 2005) .
Epigenetic mechanisms may be responsible for CDKN1C/p57 downregulation in HCC, accounting in our experience for 26% of cases, in which a gain of imprinting for CDKN1C gene is observed (Schwienbacher et al., 2000) . For this reason HCC samples with a downregulation of CDKN1C/p57 mRNA were excluded from the analysis. The same selection criteria were not applied for CDKN1B/p27 expression as previous reports on CDKN1B/p27 regulation in HCC failed to demonstrate epigenetic mechanisms affecting its transcription (Lei et al., 2005) . Previous reports have outlined that Skp1/Cul1/F-box protein E3 ubiquitin ligase-mediated degradation is important in the regulation of CDKN1B/p27 levels (Lee and Yang, 2001) . Besides this pathway, here we describe a post-transcriptional mechanism contributing to the regulation of CDKN1B/p27 levels in HCC cells. Similar findings outlining the strict relationship between CDKN1B/p27 protein levels and miR-221 expression were previously reported in glioblastoma and prostate carcinoma (Galardi et al., 2007; Le Sage et al., 2007) , consistently with the presence of different levels of regulation of CDKN1B/p27 in several neoplasms.
Our data, in line with those reported in the literature (Ito et al., 2001; Nan et al., 2005) , show that CDKN1C/ p57 is downregulated in more than 80% of HCCs, indicating the existence of more than one mechanism affecting CDKN1C/p57 expression in HCC. In this article we describe miR-221 as a direct regulator of CDKN1C/p57 expression in HCC, showing a new mechanism responsible for CDKN1C/p57 downregulation in HCC. These findings, together with those previously reported on CDKN1B/p27 modulation by miR-221, further outline the importance of this miRNA in liver carcinogenesis. Both CDKN1C/p57 and CDKN1B/p27 were previously described as involved in HCC development and as biomarkers of poor prognosis in HCC (Hui et al., 1998; Nan et al., 2004 Nan et al., , 2005 . The identification of a common regulator of both these CDKIs is, therefore, of great potential relevance, as its modulation might deeply impact deregulation of cell cycle, affecting both CDKN1B/p27 and CDKN1C/ p57 proteins. The biological significance of our findings was outlined in HCC-derived cell lines, where miR-221 and antimiR-221 transfection caused a significant modification of cell growth. In particular, cell growth inhibition by antimiR-221 appears of great relevance due to its possible therapeutic role.
In conclusion, our results suggest that miR-221, which is upregulated in 71% of HCCs, has an oncogenic function through the inhibition of CDKN1C/p57 and CDKN1B/p27 protein expression. These findings provide the basis toward the development of potential therapeutic strategies aimed at blocking miR-221 expression in HCC.
Materials and methods
Patients
Matched HCC and cirrhotic tissues were obtained from 39 consecutive patients (31 men and 8 women, median age: 70.0, range: 51-82) undergoing liver resection at the Center for Liver Surgery and Transplantation of the University of Bologna, after obtaining their informed consent. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Tissue samples were collected at surgery, and divided in two parts: one was immediately frozen in liquid nitrogen and stored at À80 1C until RNA and protein extraction; the other was fixed in 10% formalin and paraffin-embedded for histopathological examination. Histopathological grading was scored according to Edmonson and Steiner's criteria (Edmonson and Steiner, 1954) . Exclusion criteria at enrollment included a previous history of local or systemic treatments for HCC and the presence of non-cirrhotic tissue surrounding the HCC nodule/s. To avoid cases in which aberrant methylation of CDKN1C/p57 promoter could represent a confusing factor to examine the role of miR-221 on CDKN1C/ p57 expression, HCC cases were further selected on the basis of similar levels of CDKN1C/p57 mRNA expression in matched HCC and cirrhotic samples. Thus 4 out of 39 patients were excluded from the analysis due to the downregulation of CDKN1C/p57 mRNA in HCC tissue with respect to matched cirrhosis. The characteristics of HCC patients included in this study are described in Table 1 .
RT-PCR
Total RNA from HCC and cirrhotic tissues and from HCCderived cell lines was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions and 2 mg of RNA was retrotranscribed with SuperScript miR-221 targets CDKN1C/p57 and CDKN1B/p27 F Fornari et al Edmonson and Steiner's criteria (Edmonson and Steiner, 1954 Northern blot analysis RNA samples (10 mg each) were electrophoresed on 15% acrylamide, 7 M urea Criterion precasted gels (Bio-Rad) and transferred onto Hybond N þ membrane (Amersham Bioscience, Piscataway, NJ, USA). Membranes were hybridized with oligonucleotide probe corresponding to the complementary sequence of mature miR-221 (5 0 -GAAACC CAGCAGACAATGTAGCT-3 0 ). The probe was 5 0 -end labeled using the polynucleotide kinase in the presence of P32-g-ATP. Hybridization was performed at 37 1C in 7% SDS, 0.2 mol l À1 Na 2 PO 4 (pH 7.0) for 16 h. Membranes were washed at 42 1C, twice with 2 Â standard saline phosphate (0.18 mol l À1 NaCl, 10 mmol l À1 phosphate pH 7.4), 1 mmol l À1 EDTA (saline sodium phosphate EDTA, SSPE), and 0.1% SDS and twice with 0.5 Â SSPE, 0.1% SDS. Stripping of the membranes was performed in boiling 0.1% SDS for 10 min. As a control for normalization of RNA expression levels, blots were hybridized with an oligonucleotide probe complementary to the U6 RNA (5 0 -GCAGGGGCCATGCTAATCTTCTCT GTATCG-3 0 ).
Cell culture SNU449 (ATCC number: CRL-2234) and SNU398 (ATCC no.: CRL-2233) cell lines were cultured with RPMI 1640, whereas Hep3B (ATCC no.: HB-8064) cell line was cultured with Minimum Essential Medium (Eagle); both media were supplemented with 10% fetal bovine serum and antibiotics.
MiRNA target prediction
The analysis of miRNA-predicted targets was performed using the algorithms TargetScan, (http://genes.mit.edu/targetscan/), PicTar (http://pictar.bio.nyu.edu/) and miRanda (http:// cbio.mskcc.org/cgi-bin/mirnaviewer/mirnaviewer.pl). To identify the genes commonly predicted by the three different algorithms we used the miRGen (http://www.diana.pcbi.upenn. edu/miRGen/v3/miRGen.html) Web site tools.
Cell transfection with miR-221 and antimiR-221
The day before transfection HCC-derived cell lines were seeded in antibiotic-free media. SNU398 and Hep3B cell lines were transfected with 100 nM of miR-221 or negative control 1 precursor miRNAs (Ambion, Austin, TX, USA). Moreover, Hep3B and SNU449 cells were transfected with 100 nM of antimiR-221 or negative control 1 miRNA inhibitors (Ambion). SNU398 cells were not transfected with antimiR-221 because of their intrinsic low miR-221 expression (Figure 1a) . Transfection of miRNAs was carried out using Lipofectamine 2000 in accordance with the manufacturer's procedure (Invitrogen). To assay the effects of miR-221 and antimiR-221 on cell proliferation, SNU398 cell line, seeded in 24-well plates at a cellular concentration of 50 000 cells per well, was transfected with 100 nM of miR-221 or negative control 1, whereas Hep3B cells were seeded at a concentration of 25 000 cells per well and transfected with 100 nM of miR-221, antimiR-221 and negative control 1 precursor or inhibitor miRNAs. Cell countings were performed using a Burker chamber at 24, 48 and 72 h after transfection. Each data point of this experiment was carried out in triplicate.
Cell-cycle analysis of miR-221-transfected Hep3B cell line Hep3B cells were transfected with miR-221 or negative control 1 precursor miRNAs at a 100 nM concentration. At 72 h after transfection, cells were collected and fixed in 70% ethanol at 4 1C for 16 h. Fixed cells were then washed once with PBS, resuspended in 500 ml PBS containing 10 mg ml À1 propidium iodide and 50 mg ml À1 RNase and incubated for 30 min at room temperature. The cells were then centrifuged at 1200 r.p.m. for 5 min, resuspended in 500 ml of PBS and analysed with Fluorescent-Activated Cell Sorter (BD FACSaria cell sorter, BD Bioscences, San Jose, CA, USA).
Luciferase activity assay
The human 3 0 UTR of CDKN1C/p57 gene was amplified by PCR using the following primers: p57-3UTR-F: 5 0 -TCTAG AGCCCAAAGAGCCC-3 0 and p57-3UTR-R: 5 0 -TCTAGA GATTAAACATTTTATATAAATGAC-3 0 and cloned into the XbaI site of the pGL3-Control vector (Promega, Madison, Wisconsin, USA), downstream of the luciferase gene, to generate the vector pGL3-p57. For luciferase assys, the HCC-derived cell lines Hep3B and SNU449 were cultured in 24-well plates and transfected with 500 ng of either pGL3-p57 or pGL3 control vector together with 50 ng of pRL-TK vector (Promega), expressing the Renilla luciferase, and 50 pmoles of miR-221 or antimiR-221 or miRNAs negative controls. Transfection was performed using Lipofectamine 2000 and OPTI-MEM I Reduced Serum Medium (Invitrogen) as described by the manufacturer. At 24 h after transfection firefly and renilla luciferase activity were measured using the Dual-Luciferase Reporter Assay (Promega). Each transfection was repeated twice in triplicate.
Real-time RT-PCR analysis of miR-221
Accurate quantitation of mature miR-221 was obtained using TaqMan MicroRNA Assays (hsa-miR-221, N/P: 4373077; Applied Biosystems, Foster City, CA, USA), as previously described (Gramantieri et al., 2007) . Briefly, 10 ng of total purified RNA was retrotranscribed using TaqMan MicroRNA Reverse Transcription kit (P/N: 4366597; Applied Biosystems), as recommended by the manufacturer. The reverse transcription (RT) reactions were subsequently incubated in the Applied Biosystems 9700 Thermocycler for 30 min at 16 1C, 30 min at 42 1C and 5 min at 85 1C. Real-time PCR was performed on the iCycler iQ Real-time detection System (BioRad), as described by TaqMan MicroRNA assays protocol. The reactions were incubated in a 96-well plate at 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min. Standard curve was calculated using four serial dilutions (1:1, 1:10, 1:100, 1:1000 starting from an initial total RNA concentration of 100 ng ml À1 ) of a pool of five HCCs total RNAs not included in this study. Since the real-time PCR reaction efficiency exceeded 98% in all experiment sets, the comparative C T method was used to calculate the expression levels of miR-221 in all samples. For each sample the internal miR-221 targets CDKN1C/p57 and CDKN1B/p27 F Fornari et al
